(Total Views: 248)
Posted On: 10/21/2022 10:35:52 AM
Post# of 63
![Avatar](https://investorshangout.com/images/ProfileImages/411968592_59827_pY--nyLE_400x400.png)
$MTNB News Article - Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% https://marketwirenews.com/news-releases/mati...93348.html
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
My Twitter: WhyteStocks